Form 8-K Vitae Pharmaceuticals, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Vitae Pharmaceuticals (VTAE) Reports In-Line Q4 Loss of 40c/Share
March 31, 2015 8:33 AM EDTVitae Pharmaceuticals (NASDAQ: VTAE) reported Q4 EPS of ($0.40), in-line with the analyst estimate of ($0.40). Revenue for the quarter came in at $161.7 thousand versus the consensus estimate of $100 thousand.
For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.
... More